Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMBA vedolizumab dose de-escalation study in inflammatory bowel disease
NL-OMON59825Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of vedolizumab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis, sponsored by Amsterdam University Medical Center. Primary endpoint: Difference in relapse rate. Started Jul 2025; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON59825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59825.